2022
Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study
Yaghi S, Shu L, Bakradze E, Omran S, Giles JA, Amar JY, Henninger N, Elnazeir M, Liberman AL, Moncrieffe K, Lu J, Sharma R, Cheng Y, Zubair AS, Simpkins AN, Li GT, Kung JC, Perez D, Heldner M, Scutelnic A, Seiffge D, Siepen B, Rothstein A, Khazaal O, Do D, Al Kasab S, Rahman LA, Mistry EA, Kerrigan D, Lafever H, Nguyen TN, Klein P, Aparicio H, Frontera J, Kuohn L, Agarwal S, Stretz C, Kala N, Jamal S, Chang A, Cutting S, Xiao H, de Havenon A, Muddasani V, Wu T, Wilson D, Nouh A, Asad SD, Qureshi A, Moore J, Khatri P, Aziz Y, Casteigne B, Khan M, Cheng Y, Mac Grory B, Weiss M, Ryan D, Vedovati MC, Paciaroni M, Siegler JE, Kamen S, Yu S, Guerrero C, Atallah E, De Marchis GM, Brehm A, Dittrich T, Psychogios M, Alvarado-Dyer R, Kass-Hout T, Prabhakaran S, Honda T, Liebeskind DS, Furie K. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study. Stroke 2022, 53: 728-738. PMID: 35143325, DOI: 10.1161/strokeaha.121.037541.Peer-Reviewed Original ResearchConceptsCerebral venous thrombosisDirect oral anticoagulantsVenous thrombosisRecurrent venous thrombosisMajor hemorrhageInclusion criteriaDirect Oral Anticoagulants Versus WarfarinMulticenter international retrospective studyInverse probabilityInternational retrospective studySystemic venous thrombosisFavorable safety profileCox regression modelMulticenter international studyAnalysis inclusion criteriaBaseline imaging dataCVT patientsOral anticoagulationComplete recanalizationDOAC treatmentOral anticoagulantsRadiological outcomesRadiographic outcomesVersus WarfarinWarfarin treatment
2021
Ischaemic stroke on anticoagulation therapy and early recurrence in acute cardioembolic stroke: the IAC study
Yaghi S, Henninger N, Giles JA, Guerrero C, Mistry E, Liberman AL, Asad D, Liu A, Nagy M, Kaushal A, Azher I, Mac Grory B, Fakhri H, Espaillat K, Pasupuleti H, Martin H, Tan J, Veerasamy M, Esenwa C, Cheng N, Moncrieffe K, Moeini-Naghani I, Siddu M, Scher E, Trivedi T, Furie KL, Keyrouz SG, Nouh A, de Havenon A, Khan M, Smith EE, Gurol ME. Ischaemic stroke on anticoagulation therapy and early recurrence in acute cardioembolic stroke: the IAC study. Journal Of Neurology Neurosurgery & Psychiatry 2021, 92: 1062-1067. PMID: 33903185, PMCID: PMC8448925, DOI: 10.1136/jnnp-2021-326166.Peer-Reviewed Original ResearchConceptsRecurrent ischemic eventsSymptomatic intracranial hemorrhageIschemic strokeIschemic eventsAtrial fibrillationAnticoagulation therapyAcute cardioembolic strokeAnticoagulation-naïve patientsInitiation of anticoagulationStroke prevention measuresComprehensive stroke centerIschemic stroke patientsAcute ischemic strokeCox regression analysisSecondary prevention strategiesCox hazard modelSICH riskAnticoagulant therapyAnticoagulation statusStroke centersCardioembolic strokeAF patientsConsecutive patientsEarly recurrenceIntracranial hemorrhage
2020
Anticoagulation Type and Early Recurrence in Cardioembolic Stroke
Yaghi S, Mistry E, Liberman AL, Giles J, Asad SD, Liu A, Nagy M, Kaushal A, Azher I, Mac Grory B, Fakhri H, Brown Espaillat K, Pasupuleti H, Martin H, Tan J, Veerasamy M, Esenwa C, Cheng N, Moncrieffe K, Moeini-Naghani I, Siddu M, Scher E, Trivedi T, Lord A, Furie K, Keyrouz S, Nouh A, Leon Guerrero CR, de Havenon A, Khan M, Henninger N. Anticoagulation Type and Early Recurrence in Cardioembolic Stroke. Stroke 2020, 51: 2724-2732. PMID: 32757753, PMCID: PMC7484360, DOI: 10.1161/strokeaha.120.028867.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnticoagulantsAtrial FibrillationBrain IschemiaEmbolismFemaleHeart DiseasesHeparin, Low-Molecular-WeightHumansIncidenceIntracranial HemorrhagesMaleMiddle AgedNeuroimagingRecurrenceRegistriesRetrospective StudiesRisk AssessmentStrokeTreatment OutcomeUnited StatesWarfarinConceptsSymptomatic intracranial hemorrhageRecurrent ischemic eventsLow molecular weight heparinAcute ischemic strokeMolecular weight heparinIschemic eventsIntracranial hemorrhageIschemic strokeAtrial fibrillationAnalysis inclusion criteriaEarly recurrenceWeight heparinInclusion criteriaSeparate Cox regression analysesComprehensive stroke centerLarge prospective studiesOral anticoagulant therapyCox regression analysisCox regression modelAnticoagulation typeDOAC treatmentStroke RegistryAnticoagulant therapyCardioembolic strokeStroke centersFactors associated with therapeutic anticoagulation status in patients with ischemic stroke and atrial fibrillation
Yaghi S, Liberman AL, Henninger N, Grory BM, Nouh A, Scher E, Giles J, Liu A, Nagy M, Kaushal A, Azher I, Fakhri H, Espaillat KB, Asad SD, Pasupuleti H, Martin H, Tan J, Veerasamy M, Esenwa C, Cheng N, Moncrieffe K, Moeini-Naghani I, Siddu M, Trivedi T, Ishida K, Frontera J, Lord A, Furie K, Keyrouz S, de Havenon A, Mistry E, Leon Guerrero CR, Khan M. Factors associated with therapeutic anticoagulation status in patients with ischemic stroke and atrial fibrillation. Journal Of Stroke And Cerebrovascular Diseases 2020, 29: 104888. PMID: 32414583, PMCID: PMC8207529, DOI: 10.1016/j.jstrokecerebrovasdis.2020.104888.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnticoagulantsAtrial FibrillationBlood CoagulationBrain IschemiaDrug MonitoringFemaleHumansInternational Normalized RatioIntracranial ArteriosclerosisMaleRecurrenceRegistriesRetrospective StudiesRisk AssessmentRisk FactorsStrokeTime FactorsTreatment OutcomeUnited StatesWarfarinConceptsStroke prevention strategiesIschemic strokeAtrial fibrillationAnticoagulation statusMore narrowingStroke sizeStroke mechanismPrevention strategiesSetting of AFInitiation of anticoagulationComprehensive stroke centerAcute ischemic strokeDirect oral anticoagulantsIschemic stroke mechanismLogistic regression modelsBinary logistic regression modelIndex strokeSubtherapeutic INRTherapeutic anticoagulationOral anticoagulantsStroke RegistryAnticoagulant statusStroke centersConsecutive patientsLuminal narrowing